WuXi XDC Cayman Inc
2268
Classifica tra le azioni
#1886
WuXi XDC Cayman Inc. operates as an investment holding company and a global... WuXi XDC Cayman Inc. operates as an investment holding company and a global contract research, development, and manufacturing organization (CRDMO), with operations spanning China, North America, Europe, and other international regions. The company's expertise covers the entire lifecycle, from discovery and research to development and manufacturing, of biopharmaceutical products. Specifically, it focuses on antibody-drug conjugates (ADCs), various bioconjugates, monoclonal antibody intermediates, and the crucial payload-linkers integral to bioconjugate synthesis. Founded in 2013 and headquartered in Wuxi, China, WuXi XDC Cayman Inc. is a subsidiary of WuXi Biologics (Cayman) Inc.
Prezzo delle azioni
$8.78
Capitalizzazione di mercato
$11.12B
Variazione (1 giorno)
-9.52%
Variazione (1 anno)
0.57%
Paese
CN
Scambia WuXi XDC Cayman Inc (2268)
Categoria
Healthcare
Rapporto P/S per WuXi XDC Cayman Inc (2268)
Rapporto P/S al October 2026 TTM: 10.77
Secondo gli ultimi rapporti finanziari e il prezzo delle azioni di WuXi XDC Cayman Inc, il rapporto P/S attuale (TTM) è 10.77. Alla fine del 2024, era pari a 8.51.
Storico del rapporto P/S per WuXi XDC Cayman Inc da 2020 a 2026
Rapporto P/S alla fine di ogni anno
| Anno | Rapporto P/S | Cambia |
|---|---|---|
| 2026 (TTM) | 10.77 | -11.24% |
| 2025 | 12.13 | 42.53% |
| 2024 | 8.51 | -42.82% |
| 2023 | 14.89 | -49.39% |
| 2022 | 29.42 | -65.94% |
| 2021 | 86.37 | -70.02% |
| 2020 | 288.11 | 0.00% |
Rapporto P/S per aziende simili o concorrenti
| Azienda | Rapporto P/S | Differenza del rapporto P/S | Il paese |
|---|---|---|---|
| 5.37 | -50.10% |
US
|
|
| 6.29 | -41.56% |
US
|
|
| 21.02 | 95.24% |
US
|
|
| 6.53 | -39.37% |
CN
|
|
| 6.80 | -36.85% |
US
|
